Stock·NYSE·Energy
Exxon Mobil Corporation (XOM)
- Market cap
- $758.81B
- P/E
- 23.75
- Dividend yield
- 2.23%
- Street target
- $181.00median of 25 analysts
- 52-week range
- $112.51 $184.59
XOM stock forecast today
Where XOM stands today, and what CleaRank Financial AI makes of it.
XOM at a glance
Exxon Mobil Corporation (XOM): Buy, 69/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($166.27 and $153.46).
- Earnings XOM beat estimates in 6 of the 7 reports in our data, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $2.6M and made no open-market purchases over the last 18 months.
- Valuation P/E of 23.8 against 18.4 for the Energy sector: a premium to peers (+29%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Exxon Mobil Corporation (XOM) Buy with a model score of 69/100.
Trend contributes most to that score: the price is 20.25% above its 200-day average and 10.99% above its 50-day average, while the 50-day sits 8.35% above the 200-day. Valuation is the main drag, with the P/E of 23.75 29.1% above the sector median (a premium to peers). The 50-day average is $166.27 and the 200-day is $153.46, and over the past year the price gained 59.93%.
Only on CleaRank
Figures we compute ourselves from XOM's own price, earnings and insider-filing history. Tap one to see it in context.
XOM stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $184.54 is 11.0% above the 50-day simple moving average of $166.27.Price above its 200-day average ›
The price is 20.3% above the 200-day simple moving average of $153.46.50-day average above the 200-day ›
The 50-day average ($166.27) is 8.3% above the 200-day average ($153.46), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 100% of its 52-week range, between $112.51 and $184.59.
XOM share price
Pick a period: each tab shows how far XOM has moved over it, to the last close.
Today's trading
Where XOM sits inside today's range and its 52-week range.
XOM fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 23.75 is 29.1% above the Energy median of 18.4.P/S below the sector median ›
The price-to-sales ratio of 2.10 is 15.9% below the sector median of 2.5.Profitable over the last 12 months ›
Net income over the last 12 months was $32.8B on revenue of $361.1B, a net margin of 9.1%.Beat estimates in most recent reports ›
XOM beat the EPS estimate in 6 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 2.23%, or $4.12 a share a year.
Key statistics
The headline figures for XOM.
As of October 26, 2026, XOM trades at $184.54, with a market value of $758.81B, a P/E ratio of 23.75 and a dividend yield of 2.23%.
What the numbers say
CleaRank Financial AI's reading of XOM's valuation, growth and risks.
XOM's P/E of 23.75 is 29.1% above the 18.4 median for Energy stocks, which makes it a premium to peers. For scale, XOM has a market capitalisation of $758.8B and trailing earnings of $7.77 per share.
With revenue growth of 44.10%, XOM is 11.3 percentage points faster than the sector median of 32.8%. The business earns a net margin of 9.07% and an operating margin of 15.86% and a return on equity of 12.58%, below the sector median of 14.2%. The balance sheet and payout round out the picture, with debt-to-equity of 0.16 and a trailing dividend yield of 2.23% ($4.12 a share a year).
The July 31, 2026 report missed the estimate by 3.03%, with EPS of $3.52 against the $3.63 that analysts had expected. In the next session the shares moved down 0.24%.
The earnings record shows 6 beats in 7 reports, but beats have not guaranteed gains: the stock fell the next day after 4 of them. The consensus EPS estimate stands at $13.29 for this fiscal year and $12.28 for next, growth of 90.2% for the current year.
With a P/E of 23.75, 29.1% above the sector median, XOM is a premium to peers, so weaker results would have to clear a higher bar. The average daily move is 1.42%, and the beta against the S&P 500 is 0.21. Insiders sold $2.6M over the last 18 months and bought none on the open market. Insider sales are often planned in advance, so they carry less weight than purchases would.
XOM against the Energy sector
How XOM compares with the median Energy stock CleaRank tracks.
Price to earnings vs sector: XOM trades at a significant premium to sector peers (+29%), suggesting market expectations for superior growth or market position.
Return vs XLE: Since May 14, 2025, XOM has gained 70.1% against a gain of 63.4% for XLE.
Performance against XLE
XOM and the Energy sector fund over the same days.
Revenue and earnings
How much XOM sells, and how much of it becomes profit.
Revenue growth: Revenue fell 4.5% in FY2025 to $324B, from $339B a year earlier.
Profit margin: The net margin was 9.2% in FY2025, down from 10.3% the year before.
Profitable: XOM earned $29.8B in FY2025.
Earnings reality check
Did XOM beat what analysts expected, and how did the stock react?
Earnings record: XOM beat the analyst estimate in 6 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 4 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 31, 2026after close | $3.63 | $3.52 | -3.03% | -0.24% | -1.54% |
| Jan 30, 2026after close | $1.69 | $1.71 | +1.18% | -2.12% | +5.41% |
| Oct 31, 2025after close | $1.82 | $1.88 | +3.30% | -0.52% | +2.50% |
| Aug 1, 2025after close | $1.56 | $1.64 | +5.13% | -2.07% | -2.59% |
| May 2, 2025after close | $1.74 | $1.76 | +1.15% | -2.77% | +1.04% |
| Jan 31, 2025after close | $1.55 | $1.67 | +7.74% | +0.24% | +1.93% |
| Nov 1, 2024after close | $1.87 | $1.92 | +2.67% | +3.18% | +5.36% |
As of October 26, 2026, XOM has beaten the analyst EPS estimate in 6 of the 7 reports in our data and fell in the first trading session after 4 of those beats; its latest report, on July 31, 2026, came in 3.03% below the estimate and the stock moved -0.24% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
XOM AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 77.4, in overbought territory.RSI above 50 ›
An RSI of 77.4 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of XOM
The score, the reasoning behind it, and what could move the price next.
Exxon Mobil Corporation (XOM) is in an uptrend: both of its moving averages sit below the price. At $184.54, the stock is 10.99% above its 50-day average of $166.27 and 20.25% above its 200-day average of $153.46. The price is also near the top of its 52-week range, 0.03% below the high of $184.59 and 64.02% above the low of $112.51.
Momentum is stretched: the 14-day RSI sits at 77.4, in the overbought zone, while the MACD line is positive. Returns have been positive across every window shown. The price climbed 19.23% over three months, 24.53% over six months and 59.93% over the past year.
Rating reaffirmed ›
Barclays kept its Overweight rating on October 19, 2026.
Source: Analyst action, Barclays, October 19, 2026
Earnings miss ›
The July 31, 2026 report missed the EPS estimate by 3.03%, and the share price fell 0.24% in the first session after it.
Source: Earnings report, July 31, 2026Analyst downgrade ›
Wells Fargo downgraded it to Equal-Weight from Overweight on October 1, 2026.
Source: Analyst action, Wells Fargo, October 1, 2026
- The closest support below the price is the 20-day EMA at $173.89. Above the price, nothing stands between it and the 52-week high.
- A 14-day RSI of 77.4 places XOM in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- After the July 31, 2026 report the share price fell 0.24% in the first session; XOM beat estimates in 6 of the 7 reports in our data.
The uptrend rests on XOM staying above its 50-day average at $166.27 and its 200-day average at $153.46; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $173.89.
With the RSI above the overbought line, momentum could cool off, which would not be unusual even while the uptrend holds.
Technical indicators
Momentum and trend for XOM, from its daily closes.
As of October 26, 2026, with XOM at $184.54, its 14-day RSI is 77.4 (overbought territory), its 50-day simple moving average is $166.27 and its 200-day is $153.46.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What XOM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, XOM's 1-year correlation of daily returns is +0.12 with S&P 500 (SPY), +0.01 with Nasdaq 100 (QQQ), -0.09 with Bitcoin (BTC) and -0.03 with gold (XAU).
XOM price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
0/3Most analysts rate it a buy ›
9 of 25 analysts rate it a buy or strong buy, 16 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $181.00 is 1.9% below the price.More buy ratings than three months ago ›
9 of 25 rate it a buy now, against 10 of 25 three months ago.
XOM Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2026 | Barclays | Maintains | Overweight |
| Oct 15, 2026 | Morgan Stanley | Maintains | Overweight |
| Oct 1, 2026 | Wells Fargo | Downgrade | Equal-Weight |
| Sep 28, 2026 | TD Cowen | Maintains | Buy |
| Sep 3, 2026 | Piper Sandler | Maintains | Neutral |
| Aug 19, 2026 | Morgan Stanley | Maintains | Overweight |
As of October 26, 2026, 25 Wall Street analysts cover XOM: 9 rate it a buy or strong buy, 16 a hold and 0 a sell or strong sell. Their 12-month price targets range from $142.00 to $206.00. The median XOM price target is $181.00, 1.9% below the price of $184.54.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
XOM trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
XOM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from XOM's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much XOM tends to move, against the market and on its own.
XOM price history and drawdowns
XOM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.42% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 57.0%, from October 2018 to October 2020, regained by January 2022.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $32,828, against $42,015 in the S&P 500 (SPY).
XOM Drawdowns & Recovery
As of October 26, 2026, XOM's worst peak-to-trough fall over the last 10 years with dividends reinvested was -57.0% (October 2018 to October 2020); it regained that peak by January 2022, 15 months after the low, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into XOM in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: XOM trailed the S&P 500 over this period: $32,828 against $42,015.
A $10,000 investment in XOM in October 2016 would be worth about $32,828 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to XOM, and which have not.
Strongest month, January: an average of +4.79%, up in 8 of 10 years.
Weakest month, December: an average of -1.42%, up in 6 of 10 years.
This month, October: has averaged +0.92%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, XOM's strongest calendar month has been January (average +4.79%, up in 8 of 10 years) and its weakest December (average -1.42%, up in 6 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
XOM stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in XOM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in XOM today could grow to about $13,075 by 2030 in the base case, with a 90th-percentile outcome near $27,183 and a 10th-percentile outcome around $6,289. The simulation models price only; at today's 2.23% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
XOM Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $241 for XOM by 2030 in the base case, from $185 today (1.3x over 4 years). The 10th-percentile path ends near $116. These are outcomes of a Monte Carlo simulation run on XOM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $137 | $197 | $285 | |
| 2028 | $126 | $211 | $354 | |
| 2029 | $120 | $226 | $425 | |
| 2030 | $116 | $241 | $502 |
Method: a lognormal simulation of XOM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
XOM insider trading
What the people running the company have bought and sold.
XOM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought XOM shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, XOM insiders reported 7 open-market sales worth $2.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 16, 2026 | Darrin L Talley
Officer
|
Sell | 1.1K | $167.9K |
| Mar 2, 2026 | Darrin L Talley
Officer
|
Sell | 2.2K | $339.3K |
| Feb 9, 2026 | Darrin L Talley
Officer
|
Sell | 3.2K | $481.8K |
| Feb 2, 2026 | Darrin L Talley
Officer
|
Sell | 5.0K | $698.8K |
| Jan 2, 2026 | Michael J Angelakis
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Angela F Braly
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Maria S Dreyfus
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Gregory C. Garland
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | John D. Harris II
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Kaisa Hietala
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Joseph L. Hooley
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Steven A Kandarian
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Alexander A Karsner
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Lawrence W. Kellner
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Dina H Powell
Director
|
Grant | 2.5K | - |
| Jan 2, 2026 | Jeffrey W Ubben
Director
|
Grant | 2.5K | - |
| Dec 18, 2025 | Neil A Chapman
Officer
|
Grant | 1.3K | - |
| Dec 17, 2025 | Darrin L Talley
Officer
|
Sell | 3.0K | $351.6K |
| Dec 15, 2025 | Darrin L Talley
Officer
|
Sell | 3.0K | $356.3K |
| Dec 12, 2025 | Michael J Angelakis
Director
|
Grant | 17.0K | - |
| Nov 25, 2025 | Daniel Ammann
Officer
|
Grant | 102.8K | - |
| Nov 25, 2025 | James R. Chapman
Officer and Treasurer
|
Grant | 32.6K | - |
| Nov 25, 2025 | Neil A Chapman
Officer
|
Grant | 117.8K | - |
| Nov 25, 2025 | Matthew Richard Crocker
Officer
|
Grant | 69.7K | - |
| Nov 25, 2025 | Leonard M. Fox
Officer
|
Grant | 45.7K | - |
| Nov 25, 2025 | Jon M. Gibbs
Officer
|
Grant | 102.8K | - |
| Nov 25, 2025 | Kathryn A Mikells
Officer
|
Grant | 105.4K | - |
| Nov 25, 2025 | Darrin L Talley
Officer
|
Grant | 50.7K | - |
| Nov 25, 2025 | Jeffrey Allen Taylor
General Counsel
|
Grant | 50.7K | - |
| Nov 25, 2025 | Jack P Williams Jr
Officer
|
Grant | 117.8K | - |
| Nov 25, 2025 | Darren W. Woods
Chief Executive Officer
|
Grant | 225.0K | - |
| Nov 3, 2025 | Gregory C. Garland
Director
|
Grant | 8.0K | - |
| Aug 22, 2025 | Darrin L Talley
Officer
|
Sell | 2.2K | $238.4K |
| May 5, 2025 | Neil A Chapman
Officer
|
Grant | 976 | - |
Source: TwelveData, from SEC Form 4 filings
XOM stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.